{
  "explicit_drug_classes": [
    "CD19/CD22-Targeted CAR-T Cell Therapy"
  ],
  "extraction_details": [
    {
      "extracted_text": "CD19/CD22 dual-target CAR-T therapy",
      "normalized_form": "CD19/CD22-Targeted CAR-T Cell Therapy",
      "class_type": "Therapeutic",
      "evidence": "Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy for refractory or relapsed burkitt lymphoma",
      "source": "abstract_title",
      "rules_applied": [
        "Rule 3: Apply Title Case",
        "Rule 8: Hyphenate target and modality",
        "Rule 10: List targets alphabetically (CD19/CD22)",
        "Rule 25: Convert CAR-T therapy to CAR-T Cell Therapy"
      ]
    },
    {
      "extracted_text": "Autologous hematopoietic stem cell transplantation",
      "normalized_form": "NA",
      "class_type": "Procedure",
      "evidence": "Autologous hematopoietic stem cell transplantation followed by",
      "source": "abstract_title",
      "rules_applied": [
        "Rule 35: Exclude procedures (transplantation)"
      ]
    }
  ],
  "reasoning": "CD19/CD22 dual-target CAR-T therapy is explicitly stated as the active intervention. Autologous hematopoietic stem cell transplantation is excluded as it is a procedure, not a drug class. The term 'refractory or relapsed' describes the disease state, not the treatment history of the drug class being evaluated."
}